<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628338</url>
  </required_header>
  <id_info>
    <org_study_id>HCC 20-092</org_study_id>
    <nct_id>NCT04628338</nct_id>
  </id_info>
  <brief_title>IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>A Pilot Study of IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Horizon Pharma USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes a safe dosing regimen IFN-γ that is sufficient to stimulate IFN-γ&#xD;
      receptors on malignant blasts in patients who developed relapsed acute myeloid leukemia (AML)&#xD;
      or myelodysplastic syndrome (MDS) after alloSCT with no active or history of III-IV acute&#xD;
      graft-versus-host disease (GVHD). It is hypothesized that IFN-γ will promote&#xD;
      graft-vs-leukemia (GVL) in patients with AML/MDS that has relapsed after alloSCT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (alloSCT) can cure patients with acute&#xD;
      myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, relapsed AML/MDS is the&#xD;
      most significant single cause of treatment failure, and the majority of relapsed patients&#xD;
      ultimately succumb. Alloreactive T cells in the donor graft can kill residual leukemia cells,&#xD;
      mediating the graft-vs-leukemia (GVL) effect. Consistent with this, recipients of T&#xD;
      cell-depleted grafts have higher rates of relapse. GVL is more potent against chronic&#xD;
      leukemias than acute myeloblastic diseases, and the higher incidence of relapse in patients&#xD;
      with AML/MDS reflects a failure in GVL.&#xD;
&#xD;
      The central goal of this pilot trial will be to explore whether IFN-γ in this setting is safe&#xD;
      and whether it has the desired biological activities on malignant blasts in vivo. IFN-γ will&#xD;
      be tested in relapsed patients as monotherapy and in conjunction with donor leukocyte&#xD;
      infusions (DLI). The clinical and biological information from this study is essential to&#xD;
      design a phase II trial with a therapeutic endpoint.&#xD;
&#xD;
      Treatment will be initiated at 100mcg (almost equal to the dose of 50 mcg/m2 for an adult)&#xD;
      three times a week, with the potential to deescalate the frequency of injection for&#xD;
      unacceptable toxicity. To explore whether this dosing regimen is sufficient to activate&#xD;
      myeloblasts, pre- and post-treatment bone marrow specimens will be harvested to analyze for&#xD;
      IFN-γ action (upregulation of HLA class I; HLA class II, ICAM-1 and phosphorylation of&#xD;
      STAT1). The primary safety concern is the development of GVHD, which is routinely monitored&#xD;
      for all alloSCT patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Upregulation HLA l (HLA-ABC)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Upregulation of HLA l (HLA-ABC) in bone marrow malignant blasts post-IFN-γ treatment, measured by the change in mean florescent intensity by flow cytometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upregulation of HLA ll (HLA-DR/DQ)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Upregulation of HLA ll (HLA-DR/DQ) in bone marrow malignant blasts post-IFN-γ treatment, measured by the change in mean florescent intensity by flow cytometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upregulation of ICAM-1</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Upregulation of ICAM-1 in bone marrow malignant blasts post-IFN-γ treatment, measured by the change in mean florescent intensity by flow cytometry as a percentage of positive cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events related to IFN-γ</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Adverse events of IFN-γ in relapsed patients after alloSCT per CTCAE v5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Generation of phosphorylated-STAT1</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Generation of phosphorylated-STAT1 in bone marrow malignant blasts post-IFN-γ treatment, measured by the change in mean florescent intensity by flow cytometry as a percentage of positive cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Malignant Blast Burden</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Change in malignant blasts number after IFN-γ therapy and subsequent donor lymphocyte infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of GVHD</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Incidence of Graft Versus Host Disease (GVHD) progression or de novo GVHD after INF-g therapy and subsequent donor lymphocyte infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of de novo GVHD</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Incidence of graft-versus-host disease (GVHD) progression after IFN-γ therapy and subsequent DLI.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myeloid Leukemia</condition>
  <condition>Allogeneic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>IFN-γ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mcg IFN-γ subcutaneously three times per week (Weeks 0-7), once per week (Weeks 8-12) (or per protocol guidance based on tolerability, response, or DLI infusions)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFN-γ (interferon gamma-1b) injection</intervention_name>
    <description>Dosage form: 100 mcg (2 million International Units) per 0.5 mL solution, administered subcutaneously Dose regimen: three times weekly (Weeks 0-7), once weekly (Weeks 8-12)</description>
    <arm_group_label>IFN-γ</arm_group_label>
    <other_name>ACTIMMUNE®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipients of allogeneic stem cell transplantation for acute myeloid leukemia or&#xD;
             myelodysplastic syndrome from a human leukocyte antigen (HLA) matched donor&#xD;
&#xD;
          -  Relapsed of primary disease with 5% to 20% of blasts in the bone marrow by flow&#xD;
             cytometry in the bone marrow with an clear leukemia-associated immunophenotype (If the&#xD;
             patient received therapy to treat the relapse, he or she must have 5-20% residual&#xD;
             blasts prior to enrollment on this study)&#xD;
&#xD;
          -  Performance status KPS score &gt;60% (ECOG 0-2)&#xD;
&#xD;
          -  No increases in systemic immunosuppression in the prior four weeks other than to&#xD;
             maintain therapeutic levels&#xD;
&#xD;
          -  No systemic corticosteroid with a dose higher than 0.5mg/kg/day prednisone or&#xD;
             equivalent&#xD;
&#xD;
          -  No history of grade IV acute GVHD&#xD;
&#xD;
          -  No new systemic immunosuppressive medications in the prior two weeks initiated due to&#xD;
             GVHD&#xD;
&#xD;
          -  Willingness to have bone marrow and peripheral blood collected as per the study&#xD;
             protocol&#xD;
&#xD;
          -  Must be able to give informed consent&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to receive IFN-γ including known hypersensitivity to&#xD;
             interferon-gamma, E. coli derived products or any component of the product&#xD;
&#xD;
          -  Subjects with a positive pregnancy test or who are breastfeeding&#xD;
&#xD;
          -  For men or women of childing bearing potential (age &lt; 50 without hysterectomy or&#xD;
             oophorectomy or documented menopause), unwilling to use effective contraception for&#xD;
             the duration of the study.&#xD;
&#xD;
          -  Primary engraftment failure&#xD;
&#xD;
          -  Active cardiac arrhythmias not controlled by medical management or current NYHA class&#xD;
             II or higher congestive heart failure&#xD;
&#xD;
          -  Active ischemic heart disease not well controlled with medications&#xD;
&#xD;
          -  A seizure disorder not well controlled by medications&#xD;
&#xD;
          -  Estimated GFR &lt;30 mL/min&#xD;
&#xD;
          -  AST/SGOT or ALT/SPOT &gt; 5 x ULN&#xD;
&#xD;
          -  Total bilirubin &gt; 3 x ULN&#xD;
&#xD;
          -  Chemotherapy (other than hypomethylating and/or venetoclax therapy) within the prior 4&#xD;
             weeks&#xD;
&#xD;
          -  Body surface area at or less than 1.5 m2, or greater than 2.5 m2 so as to minimize the&#xD;
             variation in IFN-γ exposure based on differences in BSA.&#xD;
&#xD;
          -  Patients less than 18 years old.&#xD;
&#xD;
          -  Pregnant or breastfeeding patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sawa Ito, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda Fukas, RN, BSN</last_name>
    <phone>412-623-6037</phone>
    <email>fukaslj@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Fukas, RN, BSN</last_name>
      <phone>412-623-6037</phone>
      <email>fukaslj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Sawa Ito, MD; PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Warren Shlomchik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Krakow</last_name>
      <phone>206-667-2535</phone>
      <email>efkrakow@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Krakow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoffrey Hill, MD; PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Sawa Ito, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>allogeneic hematopoietic stem cell transplantation</keyword>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>alloSCT</keyword>
  <keyword>GVHD</keyword>
  <keyword>interferon-gamma-1b</keyword>
  <keyword>Actimmune</keyword>
  <keyword>IFN-g</keyword>
  <keyword>donor lymphocyte infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

